Kimberly Gudzune, MD, MPH, DABOM

Kimberly Gudzune, MD, MPH, is the chief medical officer for the American Board of Obesity Medicine Foundation (ABOM Foundation), where she leads initiatives supporting the field of obesity medicine including strategy development and execution, clinical and outcomes research, and engagement of ABOM-certified obesity medicine physicians.

Dr. Gudzune attended Tulane University, where she received her doctor of medicine and master's in public health. She completed her training in internal medicine at the University of Maryland Medical System. After residency, she completed a clinical research fellowship at the Johns Hopkins University School of Medicine. She also previously served as the medical director of the American Board of Obesity Medicine, where she oversaw the certification exam for physicians in obesity medicine.

Prior to assuming the chief medical officer role in 2024, Gudzune was an associate professor at the Johns Hopkins University School of Medicine. She founded and directed the Johns Hopkins Healthful Eating, Activity, and Weight Program, which provides patient-centered experiences for the delivery of multidisciplinary, evidence-based clinical services to manage obesity and its related conditions through lifestyle changes, medication management, and periprocedural care. She is board-certified in internal medicine and obesity medicine, and she has been practicing obesity medicine since 2010.

• Bachelor of Arts (BA) in Environmental Biology, University of Colorado at Boulder
• Master of Public Health (MPH) in International Health and Development, Tulane University, New Orleans, Louisiana
• Doctor of Medicine (MD), Tulane University
• Residency in Internal Medicine, University of Maryland Medical System
• Fellowship in General Internal Medicine, Johns Hopkins University, Baltimore

• Board-certified in Internal Medicine
• Board-certified in Obesity Medicine

• Elected Fellow (FTOS), The Obesity Society, 2018
• Top Doctor for Weight Management, Baltimore Magazine, 2019–2023
• Top Poster Award, The Obesity Society, 2013, 2014, 2015, 2016, 2018
• 125 Hopkins Hero awards, Johns Hopkins University School of Medicine, 2018
• Junior Investigator Special Acknowledgement Award, Annals of Internal Medicine, 2016
• Frederick L Brancati Excellence in Mentoring Award, Department of Medicine at Johns Hopkins University School of Medicine, 2015

• Committee Member, Obesity Medicine Fellowship Council
• Member, Past Chair of the Clinical Science Section, The Obesity Society (TOS)
• Member, Obesity Medicine Association (OMA)
• Professional Practice Committee Member for Standards of Care in Overweight & Obesity, American Diabetes Association (ADA)
• American Diabetes Association Professional Practice Committee Member, American Board of Obesity Medicine Foundation
• Member, American Medical Association

• Swift D. Kimberly Gudzune on Practice Patterns Among Obesity Care Clinicians. MedPage Today. May 2025.
• Pellek A. What's the Best Strategy for Severe Obesity Treatment? MedCentral. November 2024.
• Coffey D. Doctors Seek Additional Obesity Training in Wake of Obesity Patient Boom. Medscape. October 2024.
• Amenabar T. What to Know About Zepbound, the Newer Weight-Loss Drug. Washington Post. November 2023.
• Livingston S. Doctors Are Racing to Get Certified to Treat Obesity as Americans Clamor for Weight-Loss Drugs. Business Insider. September 2023.
• Brody L. From A to Zepbound: A Complete Guide to the Wonder Weight-Loss Drugs. Oprah Daily. September 2023.
• Brown C. High Price and Demand for Semaglutide Means Lack of Access for US Patients. The BMJ. August 2023.
• Petersen A. Ozempic Can Make You Thin, Not Necessarily Healthy. The Wall Street Journal. June 2023.
• Goodman B. As the Market for New Weight Loss Drugs Soars, People With Diabetes Pay the Price. CNN. December 2022.